52‐week ivarmacitinib in moderate‐to‐severe atopic dermatitis: A phase 3 trial
- 2 September 2026
- journal article
- research article
- Published by Wiley in Journal of the European Academy of Dermatology and Venereology
Abstract
Background: Ivarmacitinib, an oral JAK1 inhibitor, improved efficacy outcomes versus placebo at Week 16 in a phase 3 trial in patients with moderate‐to‐severe atopic dermatitis (AD). Objectives: To describe efficacy and safety outcomes through Week 52. Methods: In this multicentre, double‐blind, phase 3 trial (NCT04875169), patients aged 12–75 years were randomized 1:1:1 to receive once‐daily oral ivarmacitinib 4 mg, ivarmacitinib 8 mg, or placebo for 16 weeks, followed by a 36‐week double‐blind extension. At Week 16, placebo‐treated patients who continued in the study were re‐randomized to ivarmacitinib 4 mg or 8 mg. Key Week 52 endpoints included Investigator's Global Assessment (IGA) 0/1 with at least a 2‐grade improvement, Eczema Area and Severity Index 75 (EASI‐75), and Worst Itch Numeric Rating Scale (WI‐NRS) response. Results: Of 336 randomized patients, 258 completed 52 weeks of treatment. Among patients initially randomized to ivarmacitinib, Week 52 IGA responses were achieved by 42.3% and 40.2% of patients in the 4 mg and 8 mg groups, respectively. EASI‐75 responses were achieved by 60.6% and 55.9%, and WI‐NRS responses by 59.6% and 45.1%, respectively. During the active‐treatment period, treatment‐emergent adverse events (TEAEs) occurred in 87.5% and 85.5% of patients in the 4 mg and 8 mg groups, respectively. The most frequent TEAEs were upper respiratory tract infection, COVID‐19, SARS‐CoV‐2 test positive, and increased blood creatine phosphokinase. Serious TEAEs occurred in 5.6% and 4.4% of patients, respectively. Conclusion: Ivarmacitinib was associated with generally maintained improvement through Week 52, with a safety profile generally consistent with that observed during the placebo‐controlled period. Because the extension phase had no placebo control after Week 16, long‐term efficacy findings should be interpreted as descriptive.Keywords
Funding Information
- Jiangsu Hengrui Medicine
This publication has 36 references indexed in Scilit:
- Ivarmacitinib for Moderate to Severe Atopic Dermatitis in Adults and AdolescentsJAMA Dermatology, 2025
- A randomized, double-blind, placebo-controlled phase II study to evaluate the efficacy and safety of ivarmacitinib (SHR0302) in adult patients with moderate-to-severe alopecia areataJournal of the American Academy of Dermatology, 2023
- Novel insights into atopic dermatitisJournal of Allergy and Clinical Immunology, 2022
- Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic DermatitisJAMA Dermatology, 2022
- JAK inhibitors in the treatment of atopic dermatitisJournal of Allergy and Clinical Immunology, 2021
- Efficacy and Safety of SHR0302, a Highly Selective Janus Kinase 1 Inhibitor, in Patients with Moderate to Severe Atopic Dermatitis: A Phase II Randomized Clinical TrialAmerican Journal of Clinical Dermatology, 2021
- Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic DermatitisJAMA Dermatology, 2020
- Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension studyJournal of the American Academy of Dermatology, 2020
- Frequency and Management of Sleep Disturbance in Adults with Atopic Dermatitis: A Systematic ReviewDermatology and Therapy, 2017
- The Patient-Oriented Eczema MeasureArchives of Dermatology, 2004